Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Feb 28 2022 | Cytokinetics announces topline results from METEORIC-HF Industry News Industry Read More Feb 28 2022 | Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders Industry News Industry Read More Feb 28 2022 | Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy Industry News Industry Read More Feb 19 2022 | Highlights From Heart Failure Awareness Week 2022 Patient News Heart Failure Awareness 365 Patient Resource Read More Feb 13 2022 | HFSA President's Update: February 2022 HFSA News President's Updates Read More Pagination First page « First Previous page ‹ Previous … Page 65 Page 66 Page 67 Page 68 Current page 69 Page 70 Page 71 Page 72 Page 73 … Next page Next › Last page Last »
Feb 28 2022 | Cytokinetics announces topline results from METEORIC-HF Industry News Industry Read More
Feb 28 2022 | Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders Industry News Industry Read More
Feb 28 2022 | Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy Industry News Industry Read More
Feb 19 2022 | Highlights From Heart Failure Awareness Week 2022 Patient News Heart Failure Awareness 365 Patient Resource Read More
